-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, OvuEe9Q7gWT1vJlPD7blCJZ5JR+usNduozYuITpAyRAC7dT1XhX7PnNHpmJWQLaz ylThhAvuUQXjH9Fz9tP83Q== 0000927016-98-003540.txt : 19980930 0000927016-98-003540.hdr.sgml : 19980930 ACCESSION NUMBER: 0000927016-98-003540 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 19980923 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 19980929 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: NITINOL MEDICAL TECHNOLOGIES INC CENTRAL INDEX KEY: 0001017259 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 954090463 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-21001 FILM NUMBER: 98717544 BUSINESS ADDRESS: STREET 1: 27 WORMWOOD STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6177370930 MAIL ADDRESS: STREET 1: 27 WORMWOOD STREET CITY: BOSTON STATE: MA ZIP: 02210 8-K 1 FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): September 23, 1998 Nitinol Medical Technologies, Inc. - -------------------------------------------------------------------------------- (Exact Name of Registrant as Specified in Its Charter) Delaware - -------------------------------------------------------------------------------- (State or Other Jurisdiction of Incorporation) 0-21001 95-4090463 - ------------------------ ----------------------------------- (Commission File Number) (I.R.S. Employer Identification No.) 27 Wormwood Street, Boston, MA 02210 - -------------------------------------------------------------------------------- (Address of Principal Executive Offices) (Zip Code) (617) 737-0930 - -------------------------------------------------------------------------------- (Registrant's Telephone Number, Including Area Code) Not Applicable - -------------------------------------------------------------------------------- (Former Name or Former Address, if Changed Since Last Report) ITEM 5. OTHER EVENTS. On September 23, 1998, Nitinol Medical Technologies, Inc. (the "Corporation") issued a press release regarding the naming of William J. Knight as Vice President of Finance and Administration and Chief Financial Officer of the Corporation. A copy of this press release is attached as an exhibit to this Form 8-K and is incorporated herein by reference. -2- ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS. (c) Exhibits: Exhibit Number Description - -------------- ----------- 99.1 Press Release dated September 23, 1998. -3- SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NITINOL MEDICAL TECHNOLOGIES, INC. Dated: September 29, 1998 By: /s/ Thomas M. Tully -------------------------- Name: Thomas M. Tully Title: President, Chief Executive Officer -4- INDEX TO EXHIBITS Exhibit Number Description - -------------- ----------- 99.1 Press Release dated September 23, 1998. EX-99.1 2 PRESS RELEASE DATED SEPTEMBER 23,1998 NEWS BULLETIN NITINOL MEDICAL TECHNOLOGIES, INC. FROM: 27 Wormwood Street FRB Boston, MA 02210-1625 (Nasdaq/NMS:NMTI) - -------------------------------------------------------------------------------- The Financial Relations Board, Inc. FOR FURTHER INFORMATION: AT THE COMPANY: AT THE FINANCIAL RELATIONS BOARD -------------- -------------------------------- Thomas M. Tully General Info: Paul Henning (212) 661-8030 President & CEO Analyst Info: Brian Gill (212) 661-8030 (617) 737-0930 Media Info: Deanne Eagle (212) 661-8030 FOR IMMEDIATE RELEASE --------------------- September 23, 1998 NITINOL MEDICAL TECHNOLOGIES, INC. NAMES WILLIAM J. KNIGHT ---------------------------------------------------------- VICE PRESIDENT AND CHIEF FINANCIAL OFFICER ------------------------------------------ Boston, MA, September 23, 1998--Nitinol Medical Technologies, Inc. (Nasdaq/NMI:NMTI) today announced the appointment of William J. Knight, 49, to the position of Vice President of Finance and Administration, Chief Financial Officer. Knight succeeds Theodore I. Pincus, who has resigned to pursue other business opportunities. Mr. Pincus will remain in a transitional consulting role until the end of November. Since August 1996, William J. Knight has been Vice President Administration and Chief Financial Officer of Zoll Medical Corporation, a medical device manufacturer with approximately $60 million of worldwide sales. From September 1989 to February 1996, Mr. Knight was Vice President, Corporate Controller of Analytical Technology, Inc., a $125 million manufacturer of scientific instrumentation. Owned by E.M. Warburg Pincus & Co., Analytical Technologies was acquired by ThermoElectron Corporation in December 1995. Commenting on Mr. Knight's appointment, Thomas M. Tully, President and Chief Executive Officer of Nitinol Medical Technologies, Inc. said, "We are very pleased to have Bill Knight join us at this stage in the growth and development of our company. He brings to us a great deal of experience in the financial management of a global manufacturing and marketing organization. Additionally, Bill has successfully integrated foreign and domestic acquisitions at both Zoll and Analytical Technology." Nitinol Medical Technologies, Inc. designs, develops and markets innovative medical devices that utilize advanced technologies and are delivered by minimally invasive procedures. The Company's products are designed to offer alternative approaches to existing complex treatments, thereby reducing patient trauma, shortening procedure, hospitalization and recovery times, and lowering overall treatment costs. The Company's patented medical devices include self-expanding stents, vena cava filters and septal repair devices. The NMT Neurosciences division serves the needs of neurosurgeons with a range of products including cerebral spinal fluid shunts, the Selector Ultrasonic Aspirator, Ruggles Surgical Instruments, the Spetzler Titanium Aneurysm Clip, and endoscopes and instrumentation for minimally invasive surgery. To receive Nitinol's latest news release and other corporate documents via FAX -- at no cost -- please dial 1-800-PRO-INFO. Enter Nitinol's symbol NMTI. This press release contains "forward-looking statements" within the meaning --------------------------------------------------------------------------- of the Private Securities Litigation Reform Act of 1995. Such forward- ---------------------------------------------------------------------- looking statements involve known and unknown risks, uncertainties or other -------------------------------------------------------------------------- factors which may cause actual results, performance or achievements of the -------------------------------------------------------------------------- Company to be materially different from any future results, performance or -------------------------------------------------------------------------- achievements expressed or implied by such forward-looking statements. --------------------------------------------------------------------- Factors that might cause such a difference include, but are not limited to, -------------------------------------------------------------------------- those discussed under the heading "Certain Factors That May Affect Future ------------------------------------------------------------------------- Results" included in the Management's Discussion and Analysis of Financial -------------------------------------------------------------------------- Condition and Results of Operations in the Company's Annual Report on Form -------------------------------------------------------------------------- 10-K for the year ended December 31, 1997. ------------------------------------------ -----END PRIVACY-ENHANCED MESSAGE-----